New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
05:55 EDTAXAS, AXAS, BWS, BWS, DXLG, DXLG, HIBB, HIBB, PGNX, PGNX, SNMX, SNMX, ZGNX, ZGNXCompanies reporting Before the Market Open on Friday, March 15
Notable companies reporting before the opening bell on Friday include Abraxas Petroleum (AXAS), Brown Shoe Co (BWS), Destination XL Group (DXLG), Hibbett Sports (HIBB), Progenics Pharmaceuticals (PGNX), Senomyx (SNMX), and Zogenix (ZGNX).
News For AXAS;BWS;DXLG;HIBB;PGNX;SNMX;ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
10:01 EDTPGNXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abbott (ABT) initiated with a Buy at Evercore ISI... Aldeyra (ALDX) initiated with a Buy at Janney Capital... Black Stone Minerals (BSM) initiated with a Neutral at Credit Suisse... Boston Scientific (BSX) initiated with a Buy at Evercore ISI... Cidara Therapeutics (CDTX) initiated with a Buy at BTIG... Coach (COH) initiated with an Underweight at BB&T... Diplomat Pharmacy (DPLO) initiated with an Outperform at Raymond James... EPIRUS (EPRS) initiated with a Buy at BTIG... Enviva (EVA) initiated with a Buy at Citigroup... General Finance Corp (GFN) initiated with an Outperform at Oppenheimer... Hortonworks (HDP) initiated with an Outperform at Oppenheimer... Jarden (JAH) initiated with a Buy at UBS... Kate Spade (KATE) initiated with a Buy at BB&T... Medtronic (MDT) initiated with a Hold at Evercore ISI... MoneyGram (MGI) initiated with a Neutral at Goldman... Opexa Therapeutics (OPXA) initiated with a Buy at Maxim... Paratek Pharmaceuticals (PRTK) initiated with a Buy at BTIG... Progenics (PGNX) initiated with a Buy at BTIG... Rite Aid (RAD) initiated with a Buy at Mizuho... St. Jude Medical (STJ) initiated with a Buy at Evercore ISI... Starwood Waypoint (SWAY) initiated with an Outperform at Wells Fargo... Talen Energy (TLN) initiated with a Hold at Deutsche Bank... Ulta Salon (ULTA) initiated with a Buy at Buckingham... Vipshop (VIPS) initiated with a Buy at Stifel... Virtu Financial (VIRT) initiated with a Neutral at Citigroup... Vista Outdoor (VSTO) initiated with a Buy at Wunderlich... ZELTIQ (ZLTQ) initiated with a Buy at Northcoast... eBay (EBAY) initiated with a Buy at Topeka.
08:44 EDTZGNXZogenix announces new efficacy data from study of low-dose fenfluramine
Zogenix announced new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria. Zogenix intends to initiate Phase 3 clinical studies for ZX008, the company's investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome. The results presented are from the latest 5-year follow-up period in a group of Dravet syndrome patients being treated with low-dose fenfluramine. This analysis, which includes ten patients from the original study group and two patients who began treatment in 2011, demonstrated that during any given year of the follow-up period, at least 80% of patients achieved a greater than or equal to 75% reduction in the frequency of seizures. In addition, three patients were seizure-free for all 5 years and five patients were seizure-free for 2 to 4 years. The use of low-dose fenfluramine in this group of patients was shown to be generally well tolerated, with the most common adverse events being transient loss of appetite and fatigue/somnolence. No clinically meaningful cardiac adverse events were noted. No patient discontinued treatment due to adverse events. In addition, a recently published translational research study to elucidate fenfluramine's mechanism of action in Dravet syndrome demonstrated the ability of fenfluramine to significantly reduce locomotion and eliminate epileptiform EEG activity in a gene knockdown zebrafish model of Dravet syndrome. These data support the clinical results obtained in the Belgium cohort of patients.
07:05 EDTBWSBrown Shoe raises FY15 EPS view to $1.84-$1.94 from $1.78-$1.88
Consensus is $1.88. Sees FY15 revenue $2.61B-$2.63B, consensus $2.62B. Sees Famous Footwear SSS up low single digits.
07:04 EDTBWSBrown Shoe reports Q1 EPS 44c, consensus 36c
Subscribe for More Information
May 26, 2015
17:39 EDTPGNXProgenics initiated with a Buy at BTIG
Subscribe for More Information
15:00 EDTBWSNotable companies reporting before tomorrow's open
Subscribe for More Information
07:30 EDTHIBBHibbett Sports positive outlook intact, says SunTrust
Subscribe for More Information
May 22, 2015
09:25 EDTHIBBOn The Fly: Pre-market Movers
Subscribe for More Information
06:32 EDTHIBBHibbett Sports cuts FY16 EPS to $2.95-$3.04 from $2.95-$3.09, consensus $3.03
Subscribe for More Information
06:31 EDTHIBBHibbett Sports reports Q1 EPS $1.09, consensus $1.13
Subscribe for More Information
May 21, 2015
15:01 EDTHIBBNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use